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Quality of life of patients with paucibacillary leprosy*
Qualidade de vida em pacientes com hanseníase paucibacilar  
Iza Maria Corrêa Bottene1 Vitor Manoel Silva dos Reis2
Abstract: BACKGROUND - Leprosy, an infectious disease caused by Mycobacterium leprae, can affect the skin and the
peripheral nervous system and, depending on the level of involvement, it can lead to severe deformities. Leprosy
is classified into two major groups: paucibacillary (up to five lesions) and multibacillary (more than five lesions).
The deformities that appear during the progress of the disease can affect the quality of life. 
OBJECTIVE - To assess quality of life of patients with paucibacillary leprosy diagnosed and treated early in the outpa-
tients´ clinic. 
METHODS - The Dermatology Life Quality Index questionnaire and ShortForm36 were applied to 49 outpatients
undergoing treatment at the Leprosy Multidisciplinary Group of the Hospital das Clínicas of the Faculdade de
Medicina of the Universidade de São Paulo. 
RESULTS - The majority of the patients (63%) did not show impairment of the quality of life, according to the results
obtained by the Dermatology Life Quality Index questionnaire. In the questionnaire Short Form-36, the scores
assessed showed slight impairment of the quality of life. 
CONCLUSION - On this study, we can conclude that this group of patients, with paucibacillary leprosy, did not show
important impairment of the quality of life. Therefore we can conclude that the earlier the diagnosis and the treat-
ment the lesser the influence on the quality of life.  
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Resumo: Fundamentos - A hanseníase, doença infecciosa causada pelo Mycobacterium leprae, pode acometer a pele
e o sistema nervoso periférico e de acordo com o grau de acometimento, levar a graves deformidades. É classificada
em dois grandes grupos: paucibacilar (até cinco lesões) e multibacilar (mais de cinco lesões). As deformidades que
podem ocorrer durante a evolução da doença levam ao comprometimento da qualidade de vida. 
OBJETIVO - Avaliar a qualidade de vida nos pacientes com hanseníase, do grupo paucibacilar, diagnosticados e tratados
precocemente e em tratamento ambulatorial. 
MÉTODOS - Aplicação dos questionários Dermatology Life Quality Index e Short Form-36 a 49 doentes em tratamento
no Ambulatório do Grupo Multidisciplinar de Hanseníase do Hospital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo. 
RESULTADOS - A maioria (63%) dos 49 doentes, não apresentou comprometimento da qualidade de vida, na aplicação
do questionário Dermatology Life Quality Index. Quanto ao questionário genérico Short Form-36, os escores alcança-
dos demonstraram pouco comprometimento da qualidade de vida. 
CONCLUSÃO - O grupo de pacientes estudados com hanseníase paucibacilar mostrou pouco comprometimento da qua-
lidade de vida levando-se em consideração os resultados obtidos nos dois questionários aplicados. Isto nos leva a con-
cluir que quanto mais precoce é o diagnóstico e o tratamento, menor é o acometimento da qualidade de vida. 
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INTRODUCTION
Leprosy is a chronic disease caused by the
Mycobacterium leprae.1 It affects primarily the periph-
eral nervous system and secondarily the skin. It can
lead to deformities, sometimes irreversible, if not
treated in time. For operational purposes, leprosy is
nowadays classified into two major groups: pau-
cibacillary (up to 5 lesions) and multibacillary (more
than five lesions).2
Brazil is one of the countries with the highest
rates of endemicity in the world, which determines the
importance of this disease in terms of public health. 
Besides the deformities, leprosy can, due to the
associated stigma, still nowadays lead to attitudes of
aversion and discrimination from society.  
Aiming at improving the capacity building of
the team involved with the patients’ care and the ther-
apeutic approach to many diseases, various question-
naires have been developed with the purpose of bet-
ter understanding the reasons of eventual compro-
mise of the quality of life.  
In leprosy, as with other diseases, the most used
instrument is the Short Form-36 (SF-36). 
The Dermatology Life Quality Index (DLQI) is
specific for dermatology, and is also used in other der-
matoses besides leprosy.3
PATIENTS AND METHODS
The group of patients studied was classified
according to the WHO (World Health Organization)
criteria and adopted by the Sanitary Dermatology
Technical Area as patients with paucibacillary leprosy.
A total of 49 patients were interviewed, 16 males and
33 females.   
Inclusion criteria: 
1. Men and women older than 18 years of age.  
2. Having the diagnosis of the disease for a peri-
od longer than 2 months, having been treated with at
least two supervised doses of the specific therapy. 
3. Paucibacillary group, except the pure neural
form, which was not part of this work as there was no
case in the studied group. 
Exclusion criteria: 
1. Patients with other important systemic dis-
eases like: diabetes mellitus under systemic treatment,
congestive heart failure, coronary insufficiency, peptic
ulcer, hepatic or renal insufficiency. 
2. Patients with other important cutaneous dis-
eases like: hard to control atopic dermatitis, psoriasis,
and vitiligo. 
3. Patients who verbally refused to take part in
the study.  
The questionnaires applied were: the
Dermatology Life Quality Index (DLQI) and the Short
Form-36 (SF-36), without the comparative purpose,
but rather the ascertainment of the quality of life in
different ways. 
The Dermatology Life Quality Index (DLQI)
consists of 10 multiple choice questions, and the
scores are assessed in the following way: without com-
promise of the quality of life (0-1), with mild compro-
mise (2-5), moderate (6-10), severe (11-20) or very
severe (21-30). 
Also used was the generic questionnaire Short
Form-36 (SF-36), which consists of 36 items, distrib-
uted into 11 questions, which are part of two main
components: the physical health component and the
mental health component.4
The physical health component (PHC) encom-
passes four domains: functional capacity (FC), physical
aspects (PA), pain (P) and overall health status (OHS).   
The mental health component (MHC) encom-
passes four domains: vitality (V), social aspects (SA),
emotional aspects (EA) and mental health (MH). 
The SF-36 scores vary from zero to 100, where
zero is considered the worst result and the 100 score
the best one, which means, in the latter example, no
compromise of the quality of life.  
The calculations of each score, in the various
domains, are done by previously determined formu-
las, and the results can be then depicted in the form
of representative graphic figures. 
RESULTS
From the 49 patients who took part in the
study, all from the paucibacillary group, 33 (67,3%)
were female and 16 (32,7%) male. In terms of the
occurrence of reactional outbreaks, 41 patients (84%)
did not have any episode and 8 patients (16%) had at
least one reactional outbreak during the treatment.  
The scores obtained from the Dermatology Life
Quality Index (DLQI) questionnaires are depicted on
graph 1, showing 63% of the patients without compro-
mise of the quality of life,  15% with mild compromise,
10% moderate, 8% severe and e 4% very severe. 
On the Short Form-36 (SF-36) questionnaire
the calculation of the median was used for each of the
eight domains, see graph 2, and the values of each
domain are presented on table 1.   
DISCUSSION
The patient with leprosy, if not treated, pro-
gresses with physical, psychological and social disabili-
ties. Because of the stigma and the lack of knowledge
in terms of the disease, the patients, sometimes, take a
long time to seek adequate and specialized treatment,
which culminates in impairment of their quality of life.  
The visible deformities and the disabilities con-
tribute to the stigmatization of the disease, both for
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the patients undergoing treatment and the ones
already cured. 
On the other hand, even patients undergoing
treatment might, during reactional outbreaks, present
with deformities, sometimes permanent, if they are
not adequately and timely treated. There is then a
decline on the quality of life. However, if we consider
well structured health programs, with early diagnosis
and active case search we can observe a decrease or
even an absence of sequelae related to the disease.  
The patients who took part in this study were
all from the paucibacillary group, therefore with less
than five lesions and, as they were diagnosed and
treated early, they also presented with a small number
of sequelae. 
The reactions were also less frequent in this
group of patients studied. 
The WHO (World Health Organization) defines
quality of life as “ the individual’s perception in terms
of their life in the context of the culture and value sys-
tems in which they live and in relation to their goals,
expectations, standards and concerns “.5
Despite the existence of leprosy for thousands
of years, even nowadays there is discrimination in
relation to the disease, mainly due to the visible defor-
mities and to the fact that, in most cases, it affects peo-
ple from low socio economic status, which also com-
promises the quality of life.6
Many studies have been published regarding
the quality of life in various dermatological diseases:
atopic dermatitis, psoriasis.7-11
In Brazil and in other countries many studies
have been published which analyzed the quality of life
in leprosy, almost always assessing patients with
advanced clinical forms of the disease, from both
multibacillary and paucibacillary groups together.12-15
In the present study the patients who answered
the questionnaire had the paucibacillary form, with
early diagnosis and treatment, therefore less prone to
reactions and sequelae from the disease.  
The instruments used in our work were: the
generic Short Form-36 (SF-36) questionnaire, with 11
questions and a total of 36 items, which encompassed
eight  domains: four part of the physical health com-
ponent (PHC): functional capacity (FC), physical
aspects (PA), pain (P), overall health status (OHS) and
four part of the mental health component (MHC):
vitality (V), social aspects (SA), emotional aspects (EA)
and mental health (MH).  
The scores vary from 0 -100, where the zero is
attributed to the worst result and 100 to the best, and
as such, the zero score means accentuated compro-
mise of the quality of life and the 100 score means no
compromise of the quality of life.  
When we analyze the median of the domains,
we can observe that there are no significant differ-
ences among them, and all domains had a high score,
demonstrating mild compromise of the quality of life
in the group of patients studied.  
The median with the lowest score was the mental
health (64), followed by vitality (65), overall health sta-
tus and pain (both with 72). Soon after comes the func-
tional capacity with 85 and then, with 100 (no compro-
mise), come the physical, social and emotional aspects. 
Another instrument used was the “Dermatology
TABLE 1: Comparison among the SF-36 domains
Domains   N. Median
Functional Capacity 49 85
Physical Aspects 49 100
Pain 49 72
Overal Health Status 49 72
Vitality 49 65
Social Aspects 49 100
Emotional Aspects 49 100
Mental Health 49 64
GRAPH 1: Sample distribution according to the Dermatology 
life quality index
GRAPH 2: Comparison between the SF-36 domains
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Life Quality Index” (DLQI), which is composed of ten
questions, with multiple choice answers. The score
varies from 0 -30, where 0 is attributed to the best
result and 30 to the worst, namely: no compromise of
the quality of life (0-1) or mild compromise (2-5),
moderate (6-10), severe (11-20) or very severe (21-30). 
In this questionnaire (DLQI), used in order to
give more consistency to the results obtained with the
SF-36, the results obtained were even more striking,
where 63% of the 49 patients did not show any com-
promise of the quality of life, while only 37% had
some level of compromise and only 4% had severe
compromise.  
This questionnaire is specific to dermatology
and has been previously applied to other dermatolog-
ical disease besides leprosy. 
Therefore, overall we obtained favorable
results, denoting mild compromise of the quality of
life in the group of patients studied.  
This is a descriptive work, and not comparative,
keeping in mind that this is a small case series of
patients from the paucibacillary group of the disease,
and these results need to be ratified by subsequent
studies with a bigger number of cases, in order to
reinforce the idea that only with early diagnosis and
treatment can we improve the quality of life of
patients with leprosy. 
CONCLUSION
According to the results obtained in this sam-
ple, in contrast with those found on the literature
published about the quality of life in leprosy, we can
see that there have been no important changes in
terms of quality of life of the patients who took part in
the study.   
From the 49 patients interviewed, 63% had no
compromise of the quality of life, 15% a mild compro-
mise, 10% moderate, 8% severe and 4% very severe
(according to the DLQI). 
All the domains of the SF-36 had a median over
64 and, from the 8 domains, 3 had a median of 100,
there is, no compromise of the quality of life.   
Maybe this is due to the early and precise diag-
nosis and immediate start of the specific treatment,
when there was no time for the sequelae to develop,
whether they are physical, social of psychological. 
This work lead us to conclude that leprosy does
not drastically compromises the quality of life if there
is an effort towards early detection and treatment  by
the health sectors.  ❑
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